Alector, Inc.

ALECSEC EDGAR

Biological Products, (No Diagnostic Substances)CIK: 1653087

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$100.6M	$133.6M	$207.1M	$21.1M	$21.2M
Research and Development Expense	$185.9M	$210.4M	$189.4M	$156.9M	$100.5M
Operating Expenses	$245.6M	$271.5M	$244.4M	$216.3M	$135.6M
Operating Income (Loss)	-$145.0M	-$137.8M	-$37.4M	-$195.2M	-$114.4M
Other Nonoperating Income (Expense)	$26.1M	$7.8M	$1.0M	$4.9M	$9.0M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$118.9M	-$130.1M	—	—	—
Income Tax Expense (Benefit)	$128.0K	$3.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$468.3M	$621.8M	$787.6M	$814.7M	$488.3M
Assets, Current	$424.8M	$565.8M	$726.4M	$749.7M	$421.5M
Cash and Cash Equivalents, at Carrying Value	$33.0M	$74.6M	$154.3M	$50.0M	$89.6M
Liabilities	$341.5M	$487.7M	$573.2M	$513.9M	$220.7M
Liabilities, Current	$125.1M	$177.9M	$93.8M	$139.6M	$68.1M
Long-term Debt	$10.0M	$10.0M	—	—	—
Accounts Payable, Current	$2.2M	$3.8M	$4.2M	$4.7M	$3.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$229.9M	-$20.3M	$298.6M	-$166.7M	-$99.3M
Net Cash Provided by (Used in) Investing Activities	$107.1M	-$159.0M	-$49.7M	-$105.1M	-$48.9M
Net Cash Provided by (Used in) Financing Activities	$81.5M	$4.5M	$30.3M	$232.1M	$172.4M
Payments to Acquire Property, Plant, and Equipment	$1.3M	$4.1M	$3.2M	$5.0M	$15.3M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)